68Ga-DOTA-TATE for Neuroendocrine Tumors

CHUS, Sherbrooke, Canada
68Ga-DOTA-TATEPhase 3RecruitingLed by Éric E Turcotte, MDResearch Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke

Study Summary

This trial is to establish the safety of a new PET radiotracer, 68Ga-DOTA-TATE, for diagnosing neuro-endocrine cancer patients. The trial is prospective, open-label, and single-center with recruitment across Canada. There is no control group.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety profile of 68Ga-DOTA-TATE
Secondary outcome measures
Generate clinical information on the impact of 68Ga-DOTA-TATE for NET patient management
Instigate the routine standard-of-care use of 68Ga-DOTA-TATE for NET patients

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Neuroendocrine cancer patientsExperimental Treatment1 Intervention
All neuroendocrine cancer patients referred by their physician and fulfilling the eligibility criteria across Canada can be recruited to the primary site of the study. Patients will be injected intravenously with 3 MBq/kg (maximum 370 MBq) of 68Ga-DOTA-TATE. 45-90 minutes following injection, patients will be imaged in a PET/CT scanner. Images will be analyzed by a trained nuclear medicine physician. Safety profile, eventual adverse effects, false positives, false negatives and any abnormal biodistribution of the radiotracer will be monitored and analysed.

Find a site

Who is running the clinical trial?

Centre de recherche du Centre hospitalier universitaire de SherbrookeLead Sponsor
54 Previous Clinical Trials
26,042 Total Patients Enrolled
1 Trials studying Neuroendocrine Tumors
2,120 Patients Enrolled for Neuroendocrine Tumors
Université de SherbrookeOTHER
282 Previous Clinical Trials
63,696 Total Patients Enrolled
Éric E Turcotte, MDPrincipal Investigator
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
3 Previous Clinical Trials
3,500 Total Patients Enrolled

Media Library

68Ga-DOTA-TATE (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT04847505 — Phase 3
Neuroendocrine Tumors Research Study Groups: Neuroendocrine cancer patients
Neuroendocrine Tumors Clinical Trial 2023: 68Ga-DOTA-TATE Highlights & Side Effects. Trial Name: NCT04847505 — Phase 3
68Ga-DOTA-TATE (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04847505 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total volume of people who can enroll in this experiment?

"Yes, this is an active trial that was first posted on January 1st 2020. The website says the study will have one site and aim to enroll 5000 patients."

Answered by AI

Are new patients being allowed to enroll in this research study?

"According to the information available on, this trial is still in need of participants. The posting date was January 1st 2020 and the most recent update was July 18th 2022. So far, only one location has been admitted into the trial, but they are hoping for 5000 patients total."

Answered by AI
~1901 spots leftby Dec 2025